{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:25:42Z","timestamp":1790893542186,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A5A2019210"],"award-info":[{"award-number":["NRF-2020R1A5A2019210"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119596","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:47:50Z","timestamp":1779932870000},"page":"119596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"200","author":[{"given":"Do-Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Hyun","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-8739","authenticated-orcid":false,"given":"Hee-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2026.119596_bib1","doi-asserted-by":"crossref","first-page":"xiii","DOI":"10.1016\/j.ncl.2024.12.001","article-title":"Parkinson disease","volume":"43","author":"Jankovic","year":"2025","journal-title":"Neurol. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-023-00622-7","article-title":"Neuropathology of incidental Lewy body & prodromal Parkinson's disease","volume":"18","author":"Koeglsperger","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"7","key":"10.1016\/j.biopha.2026.119596_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2026.119596_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.biopha.2026.119596_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101618","article-title":"Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease","volume":"78","author":"Kip","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12974-023-02723-y","article-title":"The reciprocal interactions between microglia and T cells in Parkinson's disease: a double-edged sword","volume":"20","author":"Xu","year":"2023","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdermsci.2021.11.007","article-title":"N6-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p\/AKT3 axis","volume":"105","author":"Xian","year":"2022","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119596_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jep.2009.11.010","article-title":"Anti-inflammatory effect of Sanshuibaihu decoction may be associated with nuclear factor-kappa B and p38 MAPK alpha in collagen-induced arthritis in rat","volume":"127","author":"Yang","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2026.119596_bib9","first-page":"1","article-title":"Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches","author":"Nossier","year":"2025","journal-title":"Mol. Divers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119596_bib11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fphar.2018.01068","article-title":"Editorial: drug repositioning: current advances and future perspectives","volume":"9","author":"Nishimura","year":"2018","journal-title":"Front. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2026.119596_bib12","first-page":"899","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2024 Update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.biopha.2026.119596_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007315","article-title":"Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: threats and issues","volume":"13","author":"Kakoti","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119596_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104841","article-title":"Protective role of anticancer drugs in neurodegenerative disorders: a drug repurposing approach","volume":"140","author":"Advani","year":"2020","journal-title":"Neurochem. Int."},{"issue":"34","key":"10.1016\/j.biopha.2026.119596_bib15","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.2174\/138161209789649330","article-title":"Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions","author":"Cuny","year":"2009","journal-title":"Curr. Pharm. Des. 15"},{"issue":"12","key":"10.1016\/j.biopha.2026.119596_bib16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119596_bib17","article-title":"Tonk, Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment","volume":"10","author":"Yadav","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"10.1016\/j.biopha.2026.119596_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102969","article-title":"A user's guide to lorlatinib","volume":"151","author":"Nagasaka","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2025.5097","article-title":"Lorlatinib in tyrosine kinase inhibitor-naive advanced ROS1-positive non-small cell lung cancer: a phase 2 nonrandomized clinical trial","volume":"12","author":"Ahn","year":"2026","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2026.119596_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/B978-0-443-18677-6.00010-5","article-title":"Repositioning of receptor tyrosine kinase inhibitors: from cancer to neurodegenerative and psychiatric disorders","author":"Mansour","year":"2023","journal-title":"Recept. Tyrosine Kinases Neurodegener. Psychiatr. Disord."},{"issue":"4","key":"10.1016\/j.biopha.2026.119596_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.onc.1200849","article-title":"Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system","volume":"14","author":"Iwahara","year":"1997","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.biopha.2026.119596_bib22","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","article-title":"ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)","volume":"14","author":"Morris","year":"1997","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2026.119596_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/cancers12020426","article-title":"Emerging roles of ALK in immunity and insights for immunotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"412","key":"10.1016\/j.biopha.2026.119596_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5689","article-title":"ALK is a therapeutic target for lethal sepsis","volume":"9","author":"Zeng","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119596_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neuron.2023.10.014","article-title":"STING signaling in the brain: molecular threats, signaling activities, and therapeutic challenges","volume":"112","author":"Yang","year":"2024","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13024-023-00672-x","article-title":"Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders","volume":"18","author":"Huang","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.biopha.2026.119596_bib28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/glia.23055","article-title":"Decrease in newly generated oligodendrocytes leads to motor dysfunctions and changed myelin structures that can be rescued by transplanted cells","volume":"64","author":"Schneider","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2026.119596_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.freeradbiomed.2021.01.015","article-title":"NQO1 mediates the anti-inflammatory effects of nootkatone in lipopolysaccharide-induced neuroinflammation by modulating the AMPK signaling pathway","volume":"164","author":"Park","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119596_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bcp.2017.07.021","article-title":"Anti-inflammatory mechanism of galangin in lipopolysaccharide-stimulated microglia: critical role of PPAR-gamma signaling pathway","volume":"144","author":"Choi","year":"2017","journal-title":"Biochem. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s40478-020-01101-6","article-title":"Mitochondrial defects in the respiratory complex I contribute to impaired translational initiation via ROS and energy homeostasis in SMA motor neurons","volume":"8","author":"Thelen","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","article-title":"Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications","volume":"15","author":"Dash","year":"2025","journal-title":"Acta Pharm. Sin. B."},{"issue":"29","key":"10.1016\/j.biopha.2026.119596_bib33","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1038\/onc.2009.125","article-title":"Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas","volume":"28","author":"Thornber","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbrc.2018.04.226","article-title":"ALK is required for NLRP3 inflammasome activation in macrophages","volume":"501","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119596_bib35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/STROKEAHA.123.045991","article-title":"Inhibition of anaplastic lymphoma kinase protects from ischemic stroke","volume":"55","author":"Hu","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.biopha.2026.119596_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12974-015-0434-1","article-title":"Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit","volume":"12","author":"Banks","year":"2015","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-024-00430-z","article-title":"Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy","volume":"13","author":"Lau","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.biopha.2026.119596_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.661838","article-title":"Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction","volume":"15","author":"Takata","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119596_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4062\/biomolther.2025.049","article-title":"MLKL inhibitor reduces oxidative stress, inflammation, and dopaminergic neuronal cell death in MPTP-induced Parkinson's disease mouse model","volume":"33","author":"Kim","year":"2025","journal-title":"Biomol. Ther. (Seoul.)"},{"key":"10.1016\/j.biopha.2026.119596_bib41","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.2147\/DDDT.S565228","article-title":"Cyp3a4-mediated in vitro metabolism and in vivo disposition of lorlatinib in rats","volume":"19","author":"Xie","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2026.119596_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.biopha.2026.119596_bib43","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/cns.14157","article-title":"Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson's disease","volume":"29","author":"Ma","year":"2023","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12974-025-03563-8","article-title":"cGAS-STING signaling in brain aging and neurodegeneration: molecular links and therapeutic perspectives","volume":"22","author":"Li","year":"2025","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2026.119596_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117991","article-title":"Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects","volume":"186","author":"Wi","year":"2025","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119596_bib46","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1007\/s12013-025-01845-9","article-title":"Oxidative stress in DNA damage and neurodegenerative diseases: unveiling the mechanisms and therapeutic opportunities","volume":"83","author":"Rahman","year":"2025","journal-title":"Cell Biochem. Biophys."},{"issue":"22","key":"10.1016\/j.biopha.2026.119596_bib47","article-title":"Ameliorating mitochondrial dysfunction of neurons by biomimetic targeting nanoparticles mediated mitochondrial biogenesis to boost the therapy of Parkinson's disease","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci. (Weinh. )."},{"issue":"46","key":"10.1016\/j.biopha.2026.119596_bib48","doi-asserted-by":"crossref","first-page":"45663","DOI":"10.1021\/acsomega.4c06546","article-title":"The impact of the blood-brain barrier and its dysfunction in Parkinson's disease: contributions to pathogenesis and progression","volume":"9","author":"Khalid Iqbal","year":"2024","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.biopha.2026.119596_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","article-title":"Striatal blood-brain barrier permeability in Parkinson's disease","volume":"35","author":"Gray","year":"2015","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib50","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2026.119596_bib51","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1089\/ars.2011.3923","article-title":"Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases","volume":"15","author":"Lehner","year":"2011","journal-title":"Antioxid. Redox Signal"},{"issue":"9","key":"10.1016\/j.biopha.2026.119596_bib52","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0271678X16655551","article-title":"Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers","volume":"36","author":"Rempe","year":"2016","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2026.119596_bib53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/antiox9080647","article-title":"Mitochondrial dysfunction, oxidative stress, and neuroinflammation: intertwined roads to neurodegeneration","volume":"9","author":"Picca","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119596_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109800","article-title":"ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models","volume":"27","author":"Bugide","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-023-00350-7","article-title":"Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer","volume":"7","author":"Katayama","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119596_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153941","article-title":"Natural Citrus flavanone 5-demethylnobiletin stimulates melanogenesis through the activation of cAMP\/CREB pathway in B16F10 cells","volume":"98","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41420-022-01027-z","article-title":"Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.biopha.2026.119596_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cells12030417","article-title":"RIPK1 regulates microglial activation in lipopolysaccharide-induced neuroinflammation and MPTP-induced Parkinson's disease mouse models","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib60","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1038\/s41598-023-35975-y","article-title":"Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and alpha-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease","volume":"13","author":"Leem","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119596_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105896","article-title":"Neuroprotective and anti-inflammatory effects of the RIPK3 inhibitor GSK872 in an MPTP-induced mouse model of Parkinson's disease","volume":"181","author":"Park","year":"2024","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.biopha.2026.119596_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0006-8993(98)00259-5","article-title":"Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation: role of inducible nitric oxide synthase","volume":"792","author":"Mayhan","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2026.119596_bib63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fncel.2014.00362","article-title":"The impact of microglial activation on blood-brain barrier in brain diseases","volume":"8","author":"da Fonseca","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119596_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20889-y","article-title":"Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer's disease","volume":"12","author":"Jana","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:57:16Z","timestamp":1787439436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S0753332226006323"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119596","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119596"}}